Spots Global Cancer Trial Database for Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
Official Title: A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer
Study ID: NCT01902251
Study Description
Brief Summary: A multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
University of Colorado - Anschutz Medical Campus, Denver, Colorado, United States
University of Chicago Medical Center, Chicago, Illinois, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Contact Details
Name: Clinical Study Manager
Affiliation: Astellas Pharma Europe B.V.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
